CC BY-NC-ND 4.0 · South Asian J Cancer
DOI: 10.1055/s-0041-1731599
Original Article

Hematopoietic Stem Cell Transplant for Hematological Malignancies: Experience from a Tertiary Care Center in Northern India and Review of Indian Data

Sanjeev Kumar Sharma
1  Center for Bone Marrow Transplant, BLK Super Speciality Hospital, New Delhi, India
,
Dharma Choudhary
1  Center for Bone Marrow Transplant, BLK Super Speciality Hospital, New Delhi, India
,
Divya Doval
1  Center for Bone Marrow Transplant, BLK Super Speciality Hospital, New Delhi, India
,
Vipin Khandelwal
1  Center for Bone Marrow Transplant, BLK Super Speciality Hospital, New Delhi, India
,
1  Center for Bone Marrow Transplant, BLK Super Speciality Hospital, New Delhi, India
,
Tina Dadu
1  Center for Bone Marrow Transplant, BLK Super Speciality Hospital, New Delhi, India
,
Anil Handoo
1  Center for Bone Marrow Transplant, BLK Super Speciality Hospital, New Delhi, India
› Author Affiliations
Funding None.

Abstract

Hematopoietic stem cell transplantation (HSCT) is the preferred treatment for high-risk and relapsed/refractory hematological malignancies. Moreover, with the improved supportive care and increasing acceptance of haploidentical transplantations as an alternative treatment modality, more patients are opting for HSCT as a definite treatment for hematological malignancies. We report here the real-world data and outcome of HSCT done for hematological malignancies at our transplant center. Five hundred and sixteen patients underwent HSCT from August 2010 to November 2019. The most common indications for allogeneic and autologous HSCT were acute myeloid leukemia and multiple myeloma, respectively. The 5-year overall survival and disease-free survival for all transplants were 65% and 33%, respectively. Though outcome of matched sibling donor allogeneic transplant is better than haploidentical donor (HID) transplant, patients having only HID can still be considered for allogeneic HSCT for high-risk diseases. The most common cause of death was infections followed by relapse of the disease.



Publication History

Publication Date:
15 October 2021 (online)

© 2021. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Private Ltd
A-12, Second Floor, Sector -2, NOIDA -201301, India